Trump administration officials have blocked a Food and Drug Administration (FDA) plan to expedite a review of a psychedelic treatment for major depression. Those officials vetoed the FDA's efforts to fast-track psychedelic treatment reviews, STAT found. The Trump administration has seen layoffs at the FDA and CDC, including Office of New Drug Director Peter Stein, who resigned Tuesday amid threats of layoffs. The head of the FDA's Division of Tobacco Products, Brian King, was fired, and several top executives from the drug, food, vaccine, and medical device industries left[3][5]. Cuts have led to the departure of important scientists, which causes problems in meeting deadlines for evaluating preparations[3]. Health Secretary Robert F. Kennedy described the cuts as necessary to cut red tape[3]. The Trump administration has also cut funding for gain-of-function research in low-control countries, including China[2]. These changes raise concerns about health sector management and emergency response[3].